Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
ICU Medical Inc Market Cap
From what 5 stock analysts predict, the share price for ICU Medical Inc (ICUI) might decrease by 9.6% in the next year. This is based on a 12-month average estimation for ICUI. Price targets go from $140 to $190. The majority of stock analysts believe ICUI is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 5 Wall Street analysts have assigned ICUI 2 buy ratings, 3 hold ratings, and 0 sell ratings. This means that analysts expect ICU Medical Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ICUI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ICUI.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jayson Bedford Raymond James | Outperform | $190 | Maintains | Sep 12, 2024 |
| Brett Fishbin Keybanc | Overweight | $147 | Maintains | Aug 8, 2024 |
| Mike Matson Needham | Hold | Reiterates | Aug 8, 2024 | |
| Jayson Bedford Raymond James | Outperform | $158 | Maintains | Aug 8, 2024 |
| Mike Matson Needham | Hold | Initiates | Jun 21, 2024 | |
| Jayson Bedford Raymond James | Outperform | $135 | Upgrade | Jun 17, 2024 |
| Brett Fishbin Keybanc | Overweight | $136 | Maintains | Feb 28, 2024 |
| Brett Fishbin Keybanc | Overweight | $134 | Initiates | Feb 6, 2024 |
| Kristen Stewart CL King | Buy | $110 | Initiates | Dec 14, 2023 |
| Matthew Mishan Keybanc | Overweight | $216 | Maintains | May 9, 2023 |
| Jayson Bedford Raymond James | Market Perform | Downgrade | Nov 8, 2022 | |
| Jayson Bedford Raymond James | Outperform | $190 | Maintains | Aug 9, 2022 |
| Matthew Mishan Keybanc | Overweight | $225 | Maintains | Aug 9, 2022 |
| Jayson Bedford Raymond James | Outperform | $208 | Maintains | Aug 8, 2022 |
| Matthew Mishan Keybanc | Overweight | $230 | Maintains | Aug 3, 2022 |
| Jayson Bedford Raymond James | Outperform | $235 | Maintains | May 10, 2022 |
| Matthew Mishan Keybanc | Overweight | $265 | Maintains | May 10, 2022 |
| Jayson Bedford Raymond James | Outperform | $265 | Maintains | Feb 28, 2022 |
| Matthew Mishan Keybanc | Overweight | $280 | Maintains | Oct 22, 2021 |
| Jayson Bedford Raymond James | Outperform | $286 | Maintains | Sep 9, 2021 |
When did it IPO
1992
Staff Count
14,000
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Vivek Jain
Market Cap
$4.38B
In 2023, ICUI generated $2.26B in revenue, which was a decrease of -0.92% from the previous year. This can be seen as a signal that ICUI's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 25 Sep 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Smiths Medical recalls Bivona tracheostomy tubes due to a defect posing serious health risks, including potential airway loss and death.
Why It Matters - The recall of Smiths Medical's tracheostomy tubes could lead to significant liability costs, regulatory scrutiny, and damage to reputation, impacting ICUI's stock performance and investor confidence.
Tue, 17 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - ICU Medical (ICUI) has reached a 52-week high. Investors are advised to review the company's fundamentals for potential future gains.
Why It Matters - ICU Medical's 52-week high signals strong performance, prompting analysis of fundamentals to assess potential for future gains, influencing investment decisions.
Wed, 21 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - ICU Medical (Nasdaq:ICUI) will participate in several investor conferences in September 2024, showcasing its innovative medical products.
Why It Matters - ICU Medical's participation in investor conferences may signal growth opportunities and enhance visibility, potentially influencing stock performance and investor sentiment.
Thu, 22 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks emphasizes its Rank system based on earnings estimates and revisions to identify strong stocks, while also monitoring value, growth, and momentum trends.
Why It Matters - The Zacks Rank system highlights stocks with favorable earnings estimates, aiding investors in identifying potential high-performing stocks based on value, growth, and momentum trends.
Wed, 07 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - ICU Medical Inc (NASDAQ:ICUI) will host its Q2 2024 earnings conference call on August 7, 2024, at 4:30 PM ET, featuring key executives and analysts from various firms.
Why It Matters - The conference call will provide insights into ICU Medical's Q2 2024 performance, offering key financial metrics and strategic updates that can influence stock valuation and investor sentiment.
Wed, 07 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - ICU Medical (ICUI) reported Q3 earnings of $1.56 per share, exceeding the Zacks estimate of $0.98, but down from $1.88 per share in the same quarter last year.
Why It Matters - ICU Medical's earnings beat estimates, indicating stronger than expected performance. However, the year-over-year decline may raise concerns about future growth prospects.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
